Senseonics delivered a quarter in which the top line and the bottom line told very different stories. The diabetes device maker reported a loss of $0.50 per share, a penny worse than the -$0.49 consensus, a 2.0% miss, and earnings fell 16.3% year over year as the loss widened from $0.43. Revenue was the opposite. Sales of $19.56 million beat the $16.43 million consensus by 19.1% and grew 141.6% year over year. Management also raised full-year 2026 revenue guidance for the third straight quarter. That is the central tension: commercial momentum around Eversense 365 is accelerating faster than expected, but the cost of building that business is rising almost as quickly.
The growth trajectory is the strongest part of the report. Revenue growth has stepped up from roughly 85% in the first quarter to 120% in the second and about 140% in the third. U.S. revenue rose about 160% to $16.8 million on record shipment volume, and active prescribers grew more than 90%. Gross margin expanded to about 62% from 43% a year ago, and from 59% and 58% in the prior two quarters. The income statement shows why. Related-party revenue fell to just $0.2 million from $3.9 million, reflecting the move of commercial operations in-house. Senseonics now captures more of the economics directly, but it also carries the full commercial cost. SG&A more than doubled to $32.3 million from $15.3 million. R&D rose to $11.7 million on work for the Gemini and Freedom sensors. The operating loss widened to $31.9 million from $19.6 million. A weighted-average share count of 65.7 million, up from 45.0 million, further diluted per-share results.
The call reinforced that demand is broadening rather than spiking. About nine of ten new starts are switchers from other glucose monitors, reorder rates are running ahead of plan, and retention metrics were described as strong. The EON Care network of inserters, the clinicians who place the implanted sensor, passed its 100-inserter year-end goal early. It handled more than 40% of U.S. insertions, and the target is now about 120. Full-year revenue guidance of $68 million to $70 million has climbed from an initial $58 million to $62 million. Through nine months revenue totals $45.8 million, so the new range implies roughly $22 million to $24 million in the fourth quarter, another sequential step up. The gross margin outlook moved to more than 60%.
The forward catalysts are tangible. The Beta Bionics integration with the iLet automated insulin system is expected to launch within weeks, with first patients possible before year-end. Freedom, a next-generation monitor with no on-body component, began first-in-human testing on October 26. A pivotal study is planned for 2027 and launch is targeted for 2028. Management framed 2027 as a "$100 million company," modestly above a consensus just under that level.
Bears still have legitimate ammunition. Revenue outside the U.S. is now expected to be about 15% of full-year sales versus the roughly 20% reiterated on prior calls. That implies lower absolute European dollars after a slower transition and slower tender upgrades. Operating expenses are now expected slightly above the high end of the $150 million to $160 million range, and cash use is tracking at the top of the $110 million to $120 million range. Cash fell to $126.6 million from about $143 million last quarter, against $55 million of debt principal. Third-quarter margin benefited from a favorable 65/35 bundled-payment mix that management expects to revert to 60/40. Additional major pump partnerships were pushed out to the 2028-2030 window. Gemini timing, previously tied to a first-quarter 2027 510(k) submission, was not reiterated. Cash-flow breakeven is targeted only shortly after Freedom launches. That leaves at least two more years of heavy burn and a real possibility of further dilution.
The market had been leaning into the growth story ahead of the report. Shares rose 49.1% from the $5.76 open after the August report to $8.59 and sit 18.7% above the 200-day moving average. They are also about 19.3% below the $10.64 52-week high set on September 30, meaning a chunk of the quarter's run-up had already been surrendered. Investor sentiment became more positive, rising from 0.13 to 0.21, a meaningful but not euphoric improvement. Earnings Whispers trend signals lean positive on sequential growth and momentum, while AVWAP remains negative, consistent with a stock that has rallied but cooled from its peak.
The bottom line is that Senseonics' penny EPS miss is far less important than the accelerating revenue, expanding margins and another guidance raise. Together they suggest the in-house commercial model is working. The quality of the story still hinges on spending discipline and the balance sheet. Losses are widening, opex and burn are drifting to the high end, Europe is lagging, and profitability remains tied to a 2028 product launch. Investors are being asked to pay for growth now and wait for leverage later.